- Adjust font sizes
The People
Principle Investigators
- Christine Pippy, M.D., MSc, F.R.C.P.C.
- Jennifer Ryan, BSc.Pharm, Pharm D, ACPR
- Valerie Price, RN CNeph(c)
Partners and Sponsors
The team at DM2 would like to thank our many partners.
- The Province of New Brunswick - in-kind support
- Pharmaceutical & Industry Partners
Amgen, The Anyware Group, AstraZeneca Canada, BioVail, Bristol-Myers Squibb, Genzyme Canada, Glaxo Smith Kline, Merck, Novo Nordisk Canada Inc., Ortho-Biotech, Pfizer, Roche, Sanofi Aventis, Servier - Research Department Atlantic Health Sciences Corporation - Ethics Research Review
- The core medical group - developed the treatment algorithm, project inception and is responsible for implementation
About DM² New Brunswick
The research team is working to better manage patients with type 2 diabetes by providing physicians with two new tools to treat type 2 diabetes.
Software (electronic patient management tool)
Our electronic patient management tool gives a patients' physician an easy algorithmic approach to the latest treatment guidelines pertaining to type 2 diabetes across all organ spectrums.
Multi-disciplinary clinic (rapid referral)
Participant physicians have an option to refer patients to a multi-disciplinary clinic. The clinic is made up of a core group of: a pharmacist, a nurse, a social worker, dietician and several specialists including a cardiologist, nephrologist, general internist and endocrinologist. Patients have access to the clinic in about 6 weeks after referral, greatly reducing standard wait times.
The multi-system disease management approach, if proven effective, could provide a model for future disease management strategies in New Brunswick and across North America.
Hypothesis: Implementation of a multi-system disease management model integrating electronic feedback for general practitioners and quick access to a multidisciplinary specialist team will demonstrate a statistically significant improvement in achieving target primary outcomes consisting of BP 130/80, Slowing of GFR decline (ml/min/yr) and HgbA1C <7%
Primary Outcomes: Reduction in blood pressure, reduction of GFR decline (ml/min/yr) and reduction in AIC
Secondary Outcomes: LDL cholesterol, development of overt nephropathy, doubling of serum creatinine or dialysis, all cause mortality, resource utilization, projected economic cost avoidance, user satisfaction (physician, patient)
